Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02616861 · ClinicalTrials.gov registry record · Phase 1

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Cyclerion Therapeutics.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT02616861: Completed Phase 1 study of Healthy, sponsored by Cyclerion Therapeutics.

NCT02616861 is a Phase 1 study of Healthy that has completed, run by Cyclerion Therapeutics. The registered enrollment target is 54 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02616861, a Phase 1 study of Healthy, has completed, sponsored by Cyclerion Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of the IW-1973 Tablet administered orally to healthy volunteers, in fed and fasted states, in a single-dose crossover study. Stage 2: To assess the safety, tolerability, PK profile, and PD effects of a range of doses of IW-1973 Tablet administered orally to healthy subjects in a 21-day, multiple ascending-dose study with optional up-titration of dose level within cohort.

Conditions Studied

Interventions

  • DRUG IW-1973
  • DRUG Matching Placebo Tablet

Study Locations (1)

Texas

  • Ironwood Investigator - San Antonio

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2015-11
Est. Completion 2016-06
Phase Phase 1
Cyclerion Therapeutics

11 total trials

What the finished NCT02616861 record still lists

NCT02616861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which IW-1973 is the first listed.

NCT02616861 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02616861 about?

NCT02616861 is a clinical study titled "Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers". Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of the IW-1973 Tablet administered orally to healthy volunteers, in fed and fasted states, in a single-dose crossover study. Stage 2: To assess the safety, tolerability, PK profile, and PD ef...

What is the current status of trial NCT02616861?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2015-11. Estimated completion is 2016-06.

What conditions does trial NCT02616861 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02616861?

The interventions under investigation include: IW-1973 (DRUG), Matching Placebo Tablet (DRUG).

Who is sponsoring clinical trial NCT02616861?

This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02616861 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02616861's enrollment target sits among peer trials

54 433rd of 1090 higher than 653 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02616861, the US trial registry maintained by the National Library of Medicine. NCT02616861 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.